Matthew Borst, MD
Treatment for patients with ovarian cancer, whether newly diagnosed or recurrent, requires an individualized approach—a component which includes patient preferences, explains Matthew Borst, MD.
In an interview, he highlighted the need for neoadjuvant therapy versus upfront surgery in newly diagnosed patients, effective treatment management for recurrent platinum-sensitive disease, and what to do in the third-line setting and beyond.
OncLive: You gave an overview of different cases at this meeting. Can you speak to the management of newly diagnosed patients?
: The first 2 cases were newly diagnosed cases, and each started with a very important question: “Should the patient’s treatment begin with surgery upfront— primary debulking surgery—or should she be treated with neoadjuvant chemotherapy?” It’s a very important treatment decision from the get-go—helping patients try to overcome ovarian cancer.
... to read the full story